$type=grid$count=5$m=0$sn=0$rm=0$show=home

[WORLD]$type=sticky$rm=0$va=0$count=4$va=0$show=home

Muslim World$type=three$h=250$c=3$author=hide$comment=hide$rm=hide$date=hide$snippet=hide$show=home

Pakistan$type=three$h=250$c=3$author=hide$comment=hide$rm=hide$date=hide$snippet=hide$show=home

$type=slider$meta=0$snip=0$rm=0$count=6$show=/Islamophobia

$type=slider$meta=0$snip=0$rm=0$count=6$show=/search/label/Pakistan

$type=slider$meta=0$snip=0$rm=0$count=6$show=/search/label/Popular

Saudi Arabia$type=two$count=2$h=250$space=1$icon=1$m=0$sn=0$rm=0$show=/search/label/Muslim%20World

Iran_$type=three$count=3$h=250$space=1$icon=1$m=0$sn=0$rm=0$show=/search/label/Muslim%20World

Palestine$type=three$author=hide$comment=hide$rm=hide$date=hide$show=/search/label/Muslim%20World

Islamophobia_$type=carousel$h=350$show=/search/label/Muslim%20World

Popular Posts All time_$type=three$meta=0$snip=0$rm=0$count=9$show=/search/label/Popular

Popular Posts Last 7 days_$type=three$meta=0$snip=0$rm=0$count=9$show=/search/label/Popular

Popular Posts Last 30 days_$type=three$meta=0$snip=0$rm=0$count=9$show=/search/label/Popular

Popular Posts Last year_$type=three$meta=0$snip=0$rm=0$count=9$show=/search/label/Popular

GlaxoSmithKline breathes easier as U.S. approves triple lung drug

SHARE:

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008.

LONDON - U.S. regulators have approved GlaxoSmithKline’s three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair.

Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting Britain’s biggest drugmaker ahead of rivals such as AstraZeneca and Novartis .

Last week, the inhaler, which GSK developed with Innoviva, also won a recommendation for approval from the European Medicines Agency.

Chief Executive Emma Walmsley sees the triple lung drug as one of three “critical” launches as GSK seeks to fill a revenue gap left by falling sales of Advair, which is expected to face U.S. generic competition sometime next year.


Its two other key new products are Shingrix, a shingles vaccine that was unanimously recommended for approval by a U.S. Food and Drug Administration (FDA) advisory panel last week, and a novel dual-drug regimen for HIV.

GSK estimates about a quarter of COPD patients are already using three drugs to control their lung disease, suggesting plentiful demand for more intensive treatment.

Such patients will now get all three medicines in one easy-to-use inhaler, although how exactly that will translate into overall sales is less easy to calculate.

The new product is likely to be attractive in some markets, since it will reduce co-payments for patients by offering a single prescription, but GSK will inevitably cannibalize sales of some of its other drugs.

At the same time, prices for inhaled respiratory medicines are continuing to decline due to increased competition.

Still, by launching Trelegy Ellipta before generic Advair hits the U.S. market, GSK will have more breathing space to switch patients to the newer product, Berenberg analysts said in a note.

GSK, whose shares were little changed in early trade on Tuesday following overnight news of the FDA approval, said it would make Trelegy Ellipta available in the United States “shortly”.

The GSK inhaler combines the drugs fluticasone furoate, umeclidinium and vilanterol, offering three different mechanisms to help open airways of patients with severe COPD. The drug is not indicated for asthma.

GSK has been the respiratory market world leader since launching its Ventolin inhaler in 1969 and Walmsley, who took over as CEO in April, has made lung disease a continuing priority for the years ahead.

In July, she announced plans to narrow the focus of the group’s drug research and allocate 80 percent of its R&D budget to respiratory and HIV/infectious diseases, along with two other potential areas of oncology and immuno-inflammation.

COMMENTS

Name

Ads,5,Afghanistan,79,Africa,28,Americas,5,Animals,37,Argentina,1,Asia,277,Australia,11,Austria,5,Bahrain,3,Bangladesh,18,Barcelona,1,Belgium,3,Brunei,1,Business,1322,Canada,5,Catalan,80,China,129,Cuba,3,Czech Republic,3,DR Congo,1,Egypt,22,Ethiopia,1,Europe,261,Fitness,14,France,28,Germany,41,Haiti,1,Headlines,11,Health,171,Hillary Clinton,199,Hong Kong,2,Hungary,1,Iceland,1,India,111,Indonesia,11,International,75,Iran,84,Iraq,78,Ireland,2,Islamophobia,19,Israel,12,Italy,4,Japan,41,Jordan,1,Kenya,7,Kosovo,1,Kuwait,3,Lebanon,2,Libya,2,Lifestyle,303,Lithuania,1,Malawi,1,Malaysia,16,Malta,1,Maxico,4,Middle East,138,Muslim World,626,Myanmar,35,Nawaz Sharif,5,Nepal,3,Netherlands,2,New Zealand,10,Niger,1,Nigeria,2,Nobel Prize,81,North Korea,58,Norway,1,Opinion,26,Pakistan,1061,Palestine,38,Philippine,17,Pics,66,Poland,3,Popular,1,Qatar,93,Rohingya,118,Russia,49,Rwanda,1,Saudi Arabia,85,Science,144,Serbia,2,Showbiz,351,Somalia,4,South Africa,2,South Korea,8,Spain,62,Sports,1328,Sudan,1,Sweden,1,Switzerland,2,Syria,113,Taiwan,3,Technology,455,Thailand,12,Today IN History,24,Top News,1033,Tunisia,1,Turkey,81,U.S.,344,UAE,22,UK,59,Ukrain,2,Venezuela,4,Videos,76,Vietnam,2,World,4893,Yemen,21,Zimbabwe,2,
ltr
item
Muslim Global: GlaxoSmithKline breathes easier as U.S. approves triple lung drug
GlaxoSmithKline breathes easier as U.S. approves triple lung drug
U.S. regulators have approved GlaxoSmithKline’s three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair.
https://2.bp.blogspot.com/-iEvSahqNe7c/WcD0ycxw1dI/AAAAAAAAhHc/wkefpf97kJQdyIB2fHlXbgBrshiNzQutwCLcBGAs/s640/A%2BGlaxoSmithKline%2Blogo.jpg
https://2.bp.blogspot.com/-iEvSahqNe7c/WcD0ycxw1dI/AAAAAAAAhHc/wkefpf97kJQdyIB2fHlXbgBrshiNzQutwCLcBGAs/s72-c/A%2BGlaxoSmithKline%2Blogo.jpg
Muslim Global
http://www.muslimglobal.com/2017/09/glaxosmithkline-breathes-easier-as-us.html
http://www.muslimglobal.com/
http://www.muslimglobal.com/
http://www.muslimglobal.com/2017/09/glaxosmithkline-breathes-easier-as-us.html
true
616431133175714168
UTF-8
Loaded All Posts Not found any posts VIEW ALL Readmore Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS CONTENT IS PREMIUM Please share to unlock Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy